A View From the Biosynthetic Bridge

Teewinot Life Sciences focuses on the biosynthetic production of pharma-grade cannabinoids.

Fantastic research around cannabinoids is being conducted worldwide on a variety of indications, including pain, cancer, metabolic disease, psychiatric disease and much more. It seems clear that there is huge potential for cannabinoids for many unmet medical needs. We still need more research and more methods to investigate the remaining cannabinoids – at the moment, THC and CBD are receiving the most attention, but given that that are over a hundred other cannabinoids, we are only scratching the surface of what could potentially be achieved. Many cannabinoids have no known chemical synthesis route and occur only fractionally in plants, making them commercially unviable to extract. A researcher may hypothesize that a certain cannabinoid will benefit a certain patient population, but unless they can get their hands on the cannabinoid, they will never find out.

We are headquartered in Tampa, Florida (which implemented the Florida Medical Marijuana Legalization Initiative in 2016); we conduct our internal research and development in Canada under license from Health Canada, and all our existing and planned intellectual property are housed by our subsidiary in Ireland.

Genesis through biosynthesis

To create biosynthetic cannabinoids, we use a production environment that replicates the internal cellular function of the cannabis plant. We can currently produce 18 different cannabinoids, which are identical to those produced by the plant. This is really important because many cannabinoids have multiple chiral centers and when chemically synthesizing cannabinoids it is difficult to avoid stereoisomers, which can have very different effects to their chemical cousins. Our processes use the same mechanism as the plant, so they end up producing the same compounds as the plant. Our approach can include a mixture of organic chemistry, synthetic biology and biocatalysis. The synthetic part refers to changing the structure of an organism, such as modifying a single-celled microbe, to encode performance of a new function required for the overall process. Biocatalysis involves using enzymes to react with a starting material to produce the desired end product. Essentially, we have engineered microorganisms to produce specific synthase enzymes found in the cannabis plant. We react these synthases with the same starting material the plant uses, which – depending on the conditions set up within the bioreactor – yields different cannabinoids.

Synthetic biology and biocatalysis are not new to the pharma industry – and are already used extensively for producing medicines. One of the benefits of our process is that it can be used to enhance a naturally occurring molecule. For example, we have developed a pro-drug of CBD that has a half-life of more than 12 hours. Standard CBD has a half-life of around 70 minutes, which means that patients may have to dose many times a day to maintain a particular blood plasma level, whereas boosting the half-life would allow for just a twice daily dose.

Compared with the botanical approach to cannabinoids, the advantages of synthesis are speed and diversity. Botanical extractions usually take between three to four months, whereas chemical synthesis takes around two months to create a limited number of specific end products. Our process takes between two and seven days, which demonstrates the speed that a biosynthetic approach can bring to cannabinoid production. In addition, a biosynthetic approach removes the need to test for the various contaminants and impurities that may exist within a botanically grown plant. Plants, after all, are living things, which makes them prone to variability, although some companies are seeking to mitigate this reality by using plant clones.

High times

For the future, my hope is that our population will recognize there is more to cannabis than getting high. I can, of course, appreciate regulators wanting to limit exposure of psychotropic drugs to the general population, but only a few cannabinoids are psychotropic, which means that a blanket ban does a tremendous disservice to the wider patient population that could be well served by the remaining non-psychotropic compounds. We are currently making the case to a variety of regulatory bodies about rethinking the categorization and scheduling of these non-psychotropic molecules to accelerate the development of new medicines.

Jeff Korentur is CEO of Teewinot Life Sciences, Tampa, FL, USA.

This feature was first published in The Medicine Maker (www.themedicinemaker.com), a sister publication of The Cannabis Scientist.